NHTCNasdaqWholesale-Miscellaneous Nondurable GoodsFiscal year ends December 31
NATURAL HEALTH TRENDS CORP
Financials through Q1 FY2026, quarter ended Mar 31, 2026Last filing: 10-Q on Jul 29, 2026
$0.94−0.03 (-3.06%)
Close on Oct 19, 2026
- Market cap
- $9.54M
- P/E (TTM)
- –
- Dividend yield
- 85.08%
Margins
Share of revenue, fiscal years 2011 to 2025
Gross margin
73.5%+0.9 pts over 5 years
Operating margin
-4.5%−5.6 pts over 5 years
Net margin
-2.2%−3.6 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | -7.4% | -6.8% | -8.5% | -17.3% | |
| Gross profit | -8.0% | -7.1% | -8.3% | -17.9% | |
| Dividend per share | 0.0% | 0.0% | 0.0% | +19.0% |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | 79.1% | 1.2% | -3.1% | |
| Return on assets | 40.5% | 0.8% | -1.9% | |
| Current ratio | 2.47 | 4.64 | 2.50 | |
| Inventory turnover | 5.1× | 3.3× | 4.0× | |
| Capex to revenue | 0.3% | 0.3% | 0.2% | |
| Diluted shares | 11M | 11M | 11M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Natural Health Trends generated $19.51M from operations and spent $46.45M on capital expenditure, dividends and share buybacks. 1% of that went back into the business.
Generated
$19.51M
Used
$46.45M
Capital expenditure$539.00K1%Dividends$45.91M99%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-2.2%
×Asset turnover0.85×
×Equity multiplier1.67×
=Return on equity, FY2025-3.1%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -2.2% | 0.85× | 1.67× | -3.1% |
| FY2024 | 1.3% | 0.69× | 1.67× | 1.5% |
| FY2023 | 1.3% | 0.58× | 1.66× | 1.2% |
| FY2022 | 0.6% | 0.54× | 1.65× | 0.6% |
| FY2021 | 1.8% | 0.59× | 1.61× | 1.7% |
| FY2020 | 1.4% | 0.55× | 1.57× | 1.2% |
| FY2019 | -7.2% | 0.56× | 1.68× | -6.8% |
| FY2018 | 16.2% | 1.21× | 1.76× | 34.4% |
| FY2017 | 11.9% | 1.28× | 1.78× | 27.2% |
| FY2016 | 19.1% | 2.11× | 1.95× | 79.1% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
2of 8 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$882.00K
- Cash generatingOperating cash flow above zero-$6.00M
- Return on assets improvedROA up on the prior year0.8% → -1.6%
- Earnings backed by cashOperating cash flow above net income-$6.00M vs -$882.00K
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose2.45 → 2.50
- No dilutionShare count did not rise11M → 11M
- Gross margin improvedGross margin up on the prior year73.98% → 73.54%
- More efficientAsset turnover rose0.62 → 0.72